Skip to content

Artificial Saliva Containing Cumin and Ginger Extract in Head and Neck Cancer Patients With Xerostomia

Efficacy and Safety of Artificial Saliva Containing Cumin and Ginger Extract in Head and Neck Cancer Patients With Xerostomia

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05872464
Enrollment
52
Registered
2023-05-24
Start date
2024-07-01
Completion date
2025-06-30
Last updated
2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Xerostomia

Brief summary

The objectives of this study are to evaluate efficacy and safety of artificial saliva containing cumin and ginger extract in head and neck cancer patients with xerostomia.

Detailed description

There are 52 patients in this study. They are divided into 2 groups which are artificial saliva containing cumin and ginger extract group (test group) 26 patients and placebo group 26 patients. The patients spray the sample into the mouth 3 times/day for 14 day. Amount of saliva, pH of saliva, xerostomia questionnaires, WHO Oral Mucositis Grading Scale, quality of life, adverse events, and satisfaction were assessed.

Interventions

Artificial saliva containing cumin and ginger extract in spray bottle

OTHERPlacebo

Placebo containing composition close to the test group without cumin and ginger extract in spray bottle

Sponsors

Chulalongkorn University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age more than 18 years * Head and neck cancer with xerostomia * 6 months post radiation * Willing to participate in this study

Exclusion criteria

* Sialolith or Sjogren's syndrome * Uncontrolled cancer * Using artificial saliva more than 2 weeks * Taking Pilocarpine or cevimeline more than 2 weeks * Allergic to cumin, ginger, xylitol, and glycerin * History of other oral mucosal diseases * Pregnancy and lactation

Design outcomes

Primary

MeasureTime frameDescription
Amount of saliva14 daysSpit saliva to the bottle for 5 min

Secondary

MeasureTime frameDescription
Xerostomia questionnaires14 daysAssessment xerostomia symptom by patient (scoring 1 to 10 point (low to high xerostomia severity)).
Oral Mucositis Grading Scale14 daysEvaluate oral mucosa by physician (scoring 0 to 4 point (none to life-threatening)).
Adverse reaction: Skin reaction14 daysFound or not found
Acid and base characteristic of saliva14 daysSpit saliva to the bottle, then take 1 piece of pH strip and dip it into the saliva for 30 seconds. Compare the color of the dipped pH strip to the color chart on pH strip box. The result shows value at pH 1-14.
Adverse reaction: Gastrointestinal trat reaction14 daysFound or not found
Quality of life of the patient14 daysAssessment quality of life by patient (scoring 1 to 120 point (high to low quality of life)).
Satisfaction of the patient14 daysAssessment satisfaction by patient (scoring 1 to 10 point (low to high satisfaction)).
Adverse reaction: Respiratory reaction14 daysFound or not found

Contacts

Primary ContactPornanong Aramwit, Professor
aramwit@gmail.com+66899217255

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026